Benzazepines

Compounds with BENZENE fused to AZEPINES.
DrugDrug NameDrug Indication
DB00186LorazepamLorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
DB00231TemazepamTemazepam is specifically indicated only for the short-term management of insomnia [FDA Label], [L5539]. Furthermore, such management is generally predominantly associated with the symptomatic relief of transient and short-term insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings [F3718]. In particular, the official prescribing information for temazepam typically specifies that the instructions issued for dispensed prescriptions of the medication should indicate specifically that patients are only expected to use the therapy for short periods of time - usually 7-10 days in general [FDA Label, F3718]. Subsequently, treatment with temazepam should usually not exceed 7 to 10 consecutive days and nor should it be prescribed in quantities exceeding a one-month supply [F3718]. Some regional prescribing information also notes that temazepam may be used for premedication prior to minor surgery or other related procedures [L5539].
DB00334OlanzapineOlanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.[A177014] Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.[FDA label] As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.[A177014] Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.[FDA label] Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.[L5936] Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.[L5939]
DB00343Diltiazem**Oral** Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.[label] Indicated for use to improve exercise tolerance in patients with chronic stable angina.[label] Indicated for the management of variant angina (Prinzmetal's angina).[L6298] **Intravenous** Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.[L6292] Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.[L6292] **Off-label** Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension,[L6289] idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.[L6298]
DB00349ClobazamFor treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
DB00404AlprazolamAlprazolam is indicated for the management of anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia.[Label] Alprazolam may also be prescribed off label for insomnia, premenstrual syndrome, and depression.[A177973]
DB00475ChlordiazepoxideFor the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
DB00546AdinazolamFor the treatment of anxiety and status epilepticus.
DB00628Clorazepic acidFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
DB00670PirenzepineFor the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer.
DB00674GalantamineFor the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
DB00690FlurazepamFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
DB00800FenoldopamFor the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.
DB00801HalazepamUsed to relieve anxiety, nervousness, and tension associated with anxiety disorders.
DB00829DiazepamIn general, diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression [F3160]. Moreover, in acute alcoholic withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens [F3160]. Furthermore, diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare "stiff man syndrome" [F3160]. Particular label information from the United Kingdom also lists particular age-specific indications, including for adults: (1) The short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg. myoclonus), (5) symptomatic treatment of acute alcohol withdrawal, (6) as oral premedication for the nervous dental patient, and (7) for premedication before surgery [L5188]. In the same UK label information, diazepam is indicated in children for: (1) control of tension and irritability in cerebral spasticity in selected cases, (2) as an adjunct to the control of muscle spasm in tetanus, and for (3) oral premedication [L5188].
DB00842OxazepamFor the treatment of anxiety disorders and alcohol withdrawal.
DB00897TriazolamFor the short-term treatment of insomnia.
DB01068ClonazepamClonazepam is indicated as monotherapy or as an adjunct in the treatment of Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures [FDA Label] [F3787]. Furthermore, clonazepam may also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides [FDA Label] [F3787]. Additionally, clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in the DSM-V [FDA Label]. Alternatively, some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements [L5572, F3796]. Such regional label data also has clonazepam indicated for most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy [F3796].
DB01205FlumazenilFor the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures.
DB01215EstazolamFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
DB01273VareniclineFor use as an aid in smoking cessation.
DB01476HaloxazolamNot Available
DB01489CamazepamCamazepam has been used in placebo controlled studies for the treatment of patients suffering from anxiety and depression.
DB01511DelorazepamMainly used as an anti-anxiety agent. Studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants; however, after 4 weeks, antidepressants showed superior anti-anxiety effects. [Wikipedia] Anti-anxiety effects also appear to be weaker in elderly patients. [1] Effectiveness has also been observed in the treatment of alcohol withdrawal. Delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal. [3]
DB01544FlunitrazepamFor short-term treatment of severe insomnias, that are not responsive to other hypnotics.
DB01545Ethyl loflazepateNot Available
DB01553CloxazolamUsed primarily as an anti-anxiety agent. Typically used short term, and may be given as a single dose of up to 100mcg/kg to reduce anxiety and tension experienced prior to surgery.
DB01558BromazepamFor the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
DB01567FludiazepamUsed for the short-term treatment of anxiety disorders.
DB01587KetazolamKetazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.
DB01588PrazepamFor the treatment of anxiety disorders.
DB01589QuazepamUsed to treat insomnia.
DB01594CinolazepamFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
DB01595NitrazepamUsed to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.
DB04865Omacetaxine mepesuccinateUsed in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
DB04982TalampanelFor the treatment of epilepsy.
DB05721EVT 201Investigated for use/treatment in insomnia.
DB06435TarazepideInvestigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).
DB06504S-8510Investigated for use/treatment in alzheimer's disease and dementia.
DB06582DextofisopamInvestigated for use/treatment in irritable bowel syndrome (IBS).
DB08811TofisopamFor the treatment of anxiety and alcohol withdrawal.
DB09166EtizolamIndicated for the treatment of generalized anxiety disorder with depression, panic disorder and insomnia.
DB09305AptazapineInvestigated for the treatment of depression.
DB11655EvacetrapibNot Available
DB11965SJG-136Not Available
DB12006BMS-906024Not Available
DB12309GI-181771XNot Available
DB12355NetazepideNot Available
DB12404RemimazolamNot Available
DB12537BenzodiazepineNot Available
DB12590IndiplonNot Available
DB12611PF-477736Not Available
DB12694CE-326597Not Available
DB13324TetrazepamNot Available
DB13335PinazepamNot Available
DB13437MedazepamNot Available
DB13643LoprazolamNot Available
DB13837DoxefazepamNot Available
DB13872LormetazepamFor the treatment of short-term insomnia [L927]
DB14028NordazepamNot Available
DB14672Oxazepam acetateNot Available
DB14715CinazepamNot Available
DB12234BMS-214662Not Available
DB14971IomazenilNot Available
DB15197RSV-604Not Available
DrugDrug NameTargetType
DB00186LorazepamTranslocator proteintarget
DB00186LorazepamUDP-glucuronosyltransferase 2B15enzyme
DB00186LorazepamGABA-A receptor (anion channel)target
DB00186LorazepamCytochrome P450 3A4enzyme
DB00231TemazepamTranslocator proteintarget
DB00231TemazepamCytochrome P450 2C19enzyme
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00231TemazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB00231TemazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00231TemazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00231TemazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit pitarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00231TemazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00231TemazepamGamma-aminobutyric acid receptor subunit thetatarget
DB00231TemazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00231TemazepamCytochrome P450 3A4enzyme
DB00231TemazepamCytochrome P450 2B6enzyme
DB00231TemazepamCytochrome P450 2C8enzyme
DB00231TemazepamCytochrome P450 2C9enzyme
DB00231TemazepamGABA-A receptor (anion channel)target
DB00334OlanzapineD(1A) dopamine receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M1target
DB00334OlanzapineMuscarinic acetylcholine receptor M3target
DB00334Olanzapine5-hydroxytryptamine receptor 2Atarget
DB00334OlanzapineD(4) dopamine receptortarget
DB00334OlanzapineHistamine H1 receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M4target
DB00334OlanzapineMuscarinic acetylcholine receptor M2target
DB00334OlanzapineD(2) dopamine receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 2Ctarget
DB00334OlanzapineD(3) dopamine receptortarget
DB00334OlanzapineAlpha-1B adrenergic receptortarget
DB00334OlanzapineCytochrome P450 1A2enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 3Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 6target
DB00334OlanzapineAlpha-1A adrenergic receptortarget
DB00334OlanzapineD(1B) dopamine receptortarget
DB00334OlanzapineSerum albumincarrier
DB00334OlanzapineAlpha-1-acid glycoprotein 1carrier
DB00334OlanzapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00334OlanzapineCytochrome P450 2D6enzyme
DB00334OlanzapineMultidrug resistance protein 1transporter
DB00334OlanzapineCytochrome P450 2C19enzyme
DB00334OlanzapineCytochrome P450 3A4enzyme
DB00334OlanzapineD(1) dopamine receptortarget
DB00334OlanzapineBeta adrenergic receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 1target
DB00334OlanzapineGABA-A receptor (benzodiazepine site)target
DB00334OlanzapineCytochrome P450 2C9enzyme
DB00334OlanzapineUDP-glucuronosyltransferase 1-4enzyme
DB00343DiltiazemVoltage-dependent calcium channel gamma-1 subunittarget
DB00343DiltiazemCytochrome P450 3A4enzyme
DB00343DiltiazemCytochrome P450 2C19enzyme
DB00343DiltiazemCytochrome P450 2D6enzyme
DB00343DiltiazemCytochrome P450 3A5enzyme
DB00343DiltiazemCytochrome P450 3A7enzyme
DB00343DiltiazemMultidrug resistance protein 1transporter
DB00343DiltiazemCytochrome P450 2C8enzyme
DB00343DiltiazemSerum albumincarrier
DB00343DiltiazemAlpha-1-acid glycoprotein 1carrier
DB00343DiltiazemVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00349ClobazamCytochrome P450 2C19enzyme
DB00349ClobazamCytochrome P450 3A4enzyme
DB00349ClobazamCytochrome P450 2B6enzyme
DB00349ClobazamCytochrome P450 2C18enzyme
DB00349ClobazamSodium- and chloride-dependent GABA transporter 1transporter
DB00349ClobazamSodium- and chloride-dependent GABA transporter 3transporter
DB00349ClobazamMultidrug resistance protein 1transporter
DB00349ClobazamGABA-A receptor (anion channel)target
DB00349ClobazamCytochrome P450 2D6enzyme
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-6target
DB00404AlprazolamTranslocator proteintarget
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-4target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00404AlprazolamCytochrome P450 3A4enzyme
DB00404AlprazolamCytochrome P450 2C9enzyme
DB00404AlprazolamCytochrome P450 3A5enzyme
DB00404AlprazolamCytochrome P450 3A7enzyme
DB00404AlprazolamGABA-A receptor (anion channel)target
DB00404AlprazolamSerum albumincarrier
DB00404Alprazolamalpha1-acid glycoproteincarrier
DB00475ChlordiazepoxideCytochrome P450 3A4enzyme
DB00475ChlordiazepoxideGABA-A receptor (anion channel)target
DB00546AdinazolamCytochrome P450 2C19enzyme
DB00546AdinazolamCytochrome P450 3A4enzyme
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit gamma-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit gamma-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit gamma-3target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit beta-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit beta-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit beta-3target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit deltatarget
DB00546AdinazolamGamma-aminobutyric acid receptor subunit epsilontarget
DB00546AdinazolamGamma-aminobutyric acid receptor subunit pitarget
DB00546AdinazolamGamma-aminobutyric acid receptor subunit rho-1target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit rho-2target
DB00546AdinazolamGamma-aminobutyric acid receptor subunit rho-3target
DB00628Clorazepic acidTranslocator proteintarget
DB00628Clorazepic acidCytochrome P450 3A4enzyme
DB00628Clorazepic acidGABA-A receptor (anion channel)target
DB00670PirenzepineMuscarinic acetylcholine receptor M1target
DB00674GalantamineAcetylcholinesterasetarget
DB00674GalantamineCytochrome P450 3A4enzyme
DB00674GalantamineCytochrome P450 2D6enzyme
DB00674GalantamineAcetylcholine receptor subunit alphatarget
DB00674GalantamineAcetylcholine receptor subunit betatarget
DB00674GalantamineAcetylcholine receptor subunit deltatarget
DB00674GalantamineAcetylcholine receptor subunit gammatarget
DB00674GalantamineAcetylcholine receptor subunit epsilontarget
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-2target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-3target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-4target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-5target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-6target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-7target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-9target
DB00674GalantamineNeuronal acetylcholine receptor subunit alpha-10target
DB00674GalantamineNeuronal acetylcholine receptor subunit beta-2target
DB00674GalantamineNeuronal acetylcholine receptor subunit beta-3target
DB00674GalantamineNeuronal acetylcholine receptor subunit beta-4target
DB00674GalantamineCholinesterasetarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit pitarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00690FlurazepamGamma-aminobutyric acid receptor subunit thetatarget
DB00690FlurazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00690FlurazepamCytochrome P450 3A4enzyme
DB00690FlurazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00690FlurazepamMultidrug resistance protein 1transporter
DB00690FlurazepamCytochrome P450 2E1enzyme
DB00690FlurazepamCytochrome P450 2A6enzyme
DB00690FlurazepamSolute carrier family 22 member 2transporter
DB00800FenoldopamD(1B) dopamine receptortarget
DB00800FenoldopamD(1A) dopamine receptortarget
DB00800FenoldopamAlpha-2B adrenergic receptortarget
DB00800FenoldopamAlpha-2C adrenergic receptortarget
DB00800FenoldopamAlpha-2A adrenergic receptortarget
DB00800FenoldopamAlpha-1B adrenergic receptortarget
DB00800FenoldopamAlpha-1D adrenergic receptortarget
DB00800FenoldopamAlpha-1A adrenergic receptortarget
DB00801HalazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00801HalazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00801HalazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00801HalazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00801HalazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00801HalazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00801HalazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00801HalazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00801HalazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00801HalazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00801HalazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00801HalazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00801HalazepamGamma-aminobutyric acid receptor subunit pitarget
DB00801HalazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00801HalazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00801HalazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00801HalazepamGABA-A receptor (anion channel)target
DB00829DiazepamTranslocator proteintarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00829DiazepamCytochrome P450 3A4enzyme
DB00829DiazepamSerum albumincarrier
DB00829DiazepamCytochrome P450 2C9enzyme
DB00829DiazepamCytochrome P450 2C19enzyme
DB00829DiazepamCytochrome P450 3A5enzyme
DB00829DiazepamCytochrome P450 3A7enzyme
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00829DiazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00829DiazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00829DiazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit pitarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00829DiazepamGamma-aminobutyric acid receptor subunit thetatarget
DB00829DiazepamMultidrug resistance protein 1transporter
DB00829DiazepamCytochrome P450 2B6enzyme
DB00829DiazepamProstaglandin G/H synthase 1enzyme
DB00829DiazepamCytochrome P450 2C18enzyme
DB00829DiazepamCytochrome P450 2C8enzyme
DB00829DiazepamCytochrome P450 2E1enzyme
DB00829DiazepamGABA-A receptor (anion channel)target
DB00842OxazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00842OxazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00842OxazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00842OxazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB00842OxazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00842OxazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB00842OxazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00842OxazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00842OxazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00842OxazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00842OxazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00842OxazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00842OxazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00842OxazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00842OxazepamGamma-aminobutyric acid receptor subunit pitarget
DB00842OxazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00842OxazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00842OxazepamGamma-aminobutyric acid receptor subunit thetatarget
DB00842OxazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00842OxazepamCytochrome P450 3A4enzyme
DB00842OxazepamCytochrome P450 3A43enzyme
DB00842OxazepamUDP-glucuronosyltransferase 2B15enzyme
DB00842OxazepamUDP-glucuronosyltransferase 2B7enzyme
DB00842OxazepamUDP-glucuronosyltransferase 1-9enzyme
DB00842OxazepamGABA-A receptor (anion channel)target
DB00897TriazolamTranslocator proteintarget
DB00897TriazolamCytochrome P450 3A4enzyme
DB00897TriazolamCytochrome P450 3A5enzyme
DB00897TriazolamCytochrome P450 3A7enzyme
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-4target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-6target
DB00897TriazolamGamma-aminobutyric acid receptor subunit beta-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit beta-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit beta-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit gamma-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit gamma-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit gamma-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit deltatarget
DB00897TriazolamGamma-aminobutyric acid receptor subunit epsilontarget
DB00897TriazolamGamma-aminobutyric acid receptor subunit pitarget
DB00897TriazolamGamma-aminobutyric acid receptor subunit rho-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit rho-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit rho-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit thetatarget
DB00897TriazolamCytochrome P450 2C8enzyme
DB00897TriazolamGABA-A receptor (anion channel)target
DB01068ClonazepamTranslocator proteintarget
DB01068ClonazepamCytochrome P450 3A4enzyme
DB01068ClonazepamSerum albumincarrier
DB01068ClonazepamCytochrome P450 2E1enzyme
DB01068ClonazepamArylamine N-acetyltransferase 2enzyme
DB01068ClonazepamGABA-A receptor (anion channel)target
DB01068ClonazepamNuclear receptor subfamily 1 group I member 2target
DB01205FlumazenilGamma-aminobutyric acid receptor subunit alpha-1target
DB01205FlumazenilGamma-aminobutyric acid receptor subunit gamma-2target
DB01205FlumazenilGamma-aminobutyric acid receptor subunit alpha-5target
DB01205FlumazenilGABA-A receptor (anion channel)target
DB01215EstazolamCytochrome P450 3A4enzyme
DB01215EstazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB01215EstazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB01215EstazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB01215EstazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB01215EstazolamGamma-aminobutyric acid receptor subunit gamma-1target
DB01215EstazolamGamma-aminobutyric acid receptor subunit gamma-2target
DB01215EstazolamGamma-aminobutyric acid receptor subunit gamma-3target
DB01215EstazolamGamma-aminobutyric acid receptor subunit beta-1target
DB01215EstazolamGamma-aminobutyric acid receptor subunit beta-2target
DB01215EstazolamGamma-aminobutyric acid receptor subunit beta-3target
DB01215EstazolamGamma-aminobutyric acid receptor subunit deltatarget
DB01215EstazolamGamma-aminobutyric acid receptor subunit epsilontarget
DB01215EstazolamGamma-aminobutyric acid receptor subunit pitarget
DB01215EstazolamGamma-aminobutyric acid receptor subunit rho-1target
DB01215EstazolamGamma-aminobutyric acid receptor subunit rho-2target
DB01215EstazolamGamma-aminobutyric acid receptor subunit rho-3target
DB01215EstazolamGABA-A receptor (anion channel)target
DB01273VareniclineNeuronal acetylcholine receptor subunit alpha-4target
DB01273VareniclineNeuronal acetylcholine receptor subunit alpha-7target
DB01273VareniclineNeuronal acetylcholine receptor subunit alpha-3target
DB01273VareniclineNeuronal acetylcholine receptor subunit alpha-6target
DB01273VareniclineNeuronal acetylcholine receptor subunit beta-2target
DB01273VareniclineSolute carrier family 22 member 2transporter
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01544FlunitrazepamTranslocator proteintarget
DB01544FlunitrazepamCytochrome P450 2C19enzyme
DB01544FlunitrazepamUDP-glucuronosyltransferase 2B7enzyme
DB01544FlunitrazepamCytochrome P450 2A6enzyme
DB01544FlunitrazepamCytochrome P450 2B6enzyme
DB01544FlunitrazepamCytochrome P450 2C9enzyme
DB01544FlunitrazepamCytochrome P450 3A4enzyme
DB01544FlunitrazepamCytochrome P450 2E1enzyme
DB01544FlunitrazepamUDP-glucuronosyltransferase 1-1enzyme
DB01544FlunitrazepamUDP-glucuronosyltransferase 1-3enzyme
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01544FlunitrazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01558BromazepamCytochrome P450 3A4enzyme
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB01558BromazepamGamma-aminobutyric acid receptor subunit beta-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit beta-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01558BromazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB01558BromazepamGamma-aminobutyric acid receptor subunit deltatarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit pitarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit rho-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit rho-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit thetatarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit rho-3target
DB01558BromazepamCytochrome P450 1A2enzyme
DB01558BromazepamCytochrome P450 2C19enzyme
DB01558BromazepamCytochrome P450 2E1enzyme
DB01567FludiazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit beta-1target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit beta-2target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit deltatarget
DB01567FludiazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB01567FludiazepamGamma-aminobutyric acid receptor subunit pitarget
DB01567FludiazepamGamma-aminobutyric acid receptor subunit rho-1target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit rho-2target
DB01567FludiazepamGamma-aminobutyric acid receptor subunit rho-3target
DB01587KetazolamTranslocator proteintarget
DB01587KetazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB01587KetazolamGamma-aminobutyric acid receptor subunit beta-1target
DB01587KetazolamGamma-aminobutyric acid receptor subunit gamma-1target
DB01587KetazolamGamma-aminobutyric acid receptor subunit deltatarget
DB01587KetazolamGamma-aminobutyric acid receptor subunit epsilontarget
DB01587KetazolamCytochrome P450 3A4enzyme
DB01587KetazolamMultidrug resistance protein 1transporter
DB01587KetazolamSerum albumincarrier
DB01588PrazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01588PrazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01588PrazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01588PrazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01588PrazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB01588PrazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01588PrazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB01588PrazepamGamma-aminobutyric acid receptor subunit beta-1target
DB01588PrazepamGamma-aminobutyric acid receptor subunit beta-2target
DB01588PrazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01588PrazepamGamma-aminobutyric acid receptor subunit deltatarget
DB01588PrazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB01588PrazepamGamma-aminobutyric acid receptor subunit pitarget
DB01588PrazepamGamma-aminobutyric acid receptor subunit rho-1target
DB01588PrazepamGamma-aminobutyric acid receptor subunit rho-2target
DB01588PrazepamGamma-aminobutyric acid receptor subunit rho-3target
DB01588PrazepamCytochrome P450 3A4enzyme
DB01588PrazepamGABA-A receptor (anion channel)target
DB01589QuazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01589QuazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01589QuazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01589QuazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01589QuazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB01589QuazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01589QuazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB01589QuazepamGamma-aminobutyric acid receptor subunit beta-1target
DB01589QuazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01589QuazepamGamma-aminobutyric acid receptor subunit deltatarget
DB01589QuazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB01589QuazepamGamma-aminobutyric acid receptor subunit pitarget
DB01589QuazepamGamma-aminobutyric acid receptor subunit rho-1target
DB01589QuazepamGamma-aminobutyric acid receptor subunit rho-2target
DB01589QuazepamGamma-aminobutyric acid receptor subunit rho-3target
DB01589QuazepamCytochrome P450 2C19enzyme
DB01589QuazepamCytochrome P450 2C9enzyme
DB01589QuazepamCytochrome P450 3A4enzyme
DB01589QuazepamGABA-A receptor (anion channel)target
DB01589QuazepamCytochrome P450 2B6enzyme
DB01594CinolazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit beta-1target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit beta-2target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit deltatarget
DB01594CinolazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB01594CinolazepamGamma-aminobutyric acid receptor subunit pitarget
DB01594CinolazepamGamma-aminobutyric acid receptor subunit rho-1target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit rho-2target
DB01594CinolazepamGamma-aminobutyric acid receptor subunit rho-3target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01595NitrazepamSodium channel protein type 1 subunit alphatarget
DB01595NitrazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit beta-1target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit beta-2target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit deltatarget
DB01595NitrazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB01595NitrazepamGamma-aminobutyric acid receptor subunit pitarget
DB01595NitrazepamGamma-aminobutyric acid receptor subunit rho-1target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit rho-2target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit rho-3target
DB01595NitrazepamGamma-aminobutyric acid receptor subunit thetatarget
DB01595NitrazepamCytochrome P450 3A4enzyme
DB01595NitrazepamCytochrome P450 2E1enzyme
DB04865Omacetaxine mepesuccinate50S ribosomal protein L2target
DB04865Omacetaxine mepesuccinate60S ribosomal protein L3target
DB04982TalampanelGlutamate receptor 1target
DB04982TalampanelGlutamate receptor 2target
DB04982TalampanelGlutamate receptor 3target
DB04982TalampanelGlutamate receptor 4target
DB08811TofisopamcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB08811TofisopamcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10Atarget
DB08811TofisopamcGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB08811TofisopamcGMP-dependent 3',5'-cyclic phosphodiesterasetarget
DB08811TofisopamCytochrome P450 3A4enzyme
DB09166EtizolamCytochrome P450 3A4enzyme
DB09166EtizolamCytochrome P450 2C18enzyme
DB09166EtizolamCytochrome P450 2C19enzyme
DB09166EtizolamPlatelet-activating factor receptortarget
DB09166EtizolamGamma-aminobutyric acid receptor subunit alpha-1target
DB09166EtizolamGamma-aminobutyric acid receptor subunit alpha-2target
DB09166EtizolamGamma-aminobutyric acid receptor subunit alpha-3target
DB09166EtizolamGamma-aminobutyric acid receptor subunit gamma-2target
DB12537BenzodiazepineCytochrome P450 3A4enzyme
DB13872LormetazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB13872LormetazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB13872LormetazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB13872LormetazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB13872LormetazepamGamma-aminobutyric acid receptor subunit alpha-1target